Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with non-small cell lung cancer (NSCLC). Although some patients can experience important response rates and improved survival, many others do not benefit from ICIs developing hyper-progressive disease or immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Costantini, Adrien, Takam Kamga, Paul, Dumenil, Coraline, Chinet, Thierry, Emile, Jean-François, Giroux Leprieur, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769436/
https://www.ncbi.nlm.nih.gov/pubmed/31470546
http://dx.doi.org/10.3390/cancers11091269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769436/
https://www.ncbi.nlm.nih.gov/pubmed/31470546
http://dx.doi.org/10.3390/cancers11091269

Ejemplares similares